Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review.
Eur J Pharmacol
; 977: 176725, 2024 Aug 15.
Article
em En
| MEDLINE
| ID: mdl-38851563
ABSTRACT
Receptor tyrosine kinases (RTKs) are cell surface receptors with kinase activity that play a crucial role in diverse cellular processes. Among the RTK family members, Human epidermal growth factor receptor 2 (HER2) and HER3 are particularly relevant to breast cancer. The review delves into the complexities of receptor tyrosine kinase interactions, resistance mechanisms, and the potential of anti-HER3 drugs, offering valuable insights into the clinical implications and future directions in this field of study. It assesses the potential of anti-HER3 drugs, such as pertuzumab, in overcoming resistance observed in HER2-positive breast cancer therapies. The review also explores the resistance mechanisms associated with various drugs, including trastuzumab, lapatinib, and PI3K inhibitors, providing insights into the intricate molecular processes underlying resistance development. The review concludes by emphasizing the necessity for further clinical trials to assess the efficacy of HER3 inhibitors and the potential of developing safe and effective anti-HER3 treatments to improve treatment outcomes for patients with HER2-positive breast cancer.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Receptor ErbB-2
/
Resistencia a Medicamentos Antineoplásicos
/
Receptor ErbB-3
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Eur J Pharmacol
/
Eur. j. pharmacol
/
European journal of pharmacology
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
China